Key result
Evinacumab achieved substantial and similar LDL-C reductions at 24 weeks in HoFH patients undergoing apheresis and those not receiving apheresis.
Why the study?
Does evinacumab reduce LDL-C and modify the need for lipoprotein apheresis in individuals with homozygous familial hypercholesterolaemia?
Does evinacumab reduce LDL-C and modify the need for lipoprotein apheresis in individuals with homozygous familial hypercholesterolaemia?
Answers are grounded in this paper and cite their sources.
Evinacumab provides robust, LDLR-independent LDL-C reductions in HoFH patients regardless of concurrent lipoprotein apheresis, potentially allowing for a reduction in apheresis frequency and treatment burden.
This editorial refers to ‘Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia’, by P.M. Moriarty et al. https://doi.org/10.1093/eurjpc/zwag182 Homozygous familial hypercholesterolaemia (HoFH) remains one of the most challenging conditions in preventive cardiology. HoFH is characterized by extreme elevations in low-density lipoprotein cholesterol (LDL-C) from birth due to genetic defects in genes affecting LDL metabolism, often the LDL receptor (LDLR), and, if untreated, confers a markedly increased risk of premature atherosclerotic cardiovascular disease (ASCVD), often manifesting very early in life.1 Current guidelines recommend immediate initiation of intensive lipid-lowering therapy at diagnosis.1 Despite major therapeutic advances, achieving recommended LDL-C goals in this population remains difficult.1 This challenge is largely explained by the underlying biology of the disease. Most conventional lipid-lowering therapies, including statins, PCSK9 inhibitors, and bempedoic acid, act by up-regulating hepatic LDLR, thereby increasing the catabolism of LDL. However, in HoFH, LDLR activity is severely impaired or absent, so responses to these therapies are markedly attenuated and largely insufficient to achieve the substantial LDL-C reduction required to lower cardiovascular risk and to achieve the LDL-C goals recommended by expert consensus groups.1 Given this pathophysiological background, lipoprotein apheresis, which acts independently of LDLR function, has been a cornerstone of care.1 Lipoprotein apheresis has historically played a key role in both paediatric and adult HoFH management, producing time-averaged LDL-C reductions of approximately 30–40%.1 However, its role is evolving, particularly with the advent of newer pharmacological options. The limitations of apheresis are well recognized: it is resource-intensive, time-consuming, burdensome for patients, and difficult to perform in young children. In this context, inhibition of angiopoietin-like 3 (ANGPTL3) with evinacumab represents a major therapeutic advance. By lowering LDL-C independently of LDLR function, evinacumab achieves reductions of approximately 50% in randomized clinical trials, with sustained efficacy in long-term follow-up.2 Importantly, these effects are consistent across subgroups, including paediatric populations.2,3 In this issue of the European Journal of Preventive Cardiology, Moriarty and colleagues report a post hoc analysis evaluating the combined use of evinacumab and lipoprotein apheresis in 138 individuals with HoFH, 43% of whom were receiving lipoprotein apheresis at baseline.4 The key clinical question addressed was whether evinacumab complements, replaces, or modifies the role of lipoprotein apheresis. At 24 weeks, LDL-C reductions with evinacumab were substantial and similar in patients undergoing apheresis (−42.9%) and in those not receiving apheresis (−50.8%).4 These findings confirm the robust LDLR-independent efficacy of evinacumab, irrespective of background therapy. Lipid reductions were sustained over time and extended to other atherogenic markers, including apolipoprotein B, non-HDL-C, and lipoprotein(a).4 Similar results have been reported in real-world settings, where evinacumab significantly reduced LDL-C levels regardless of concomitant apheresis.5 Beyond lipid lowering, the most notable finding concerns treatment burden. Among patients undergoing lipoprotein apheresis at baseline, nearly one-third experienced a reduction in treatment frequency, while only a small minority required intensification. Although exploratory, these findings suggest that treatment with evinacumab can enable a de-intensification strategy, reducing dependence on a highly life-limiting therapy without compromising lipid control. Rather than representing competing strategies, evinacumab and lipoprotein apheresis may be complementary approaches. The combination of acute lipoprotein removal with sustained LDLR-independent pharmacological lowering may optimize lipid control in a patient-centred model, allowing therapy to be tailored to clinical need and response, while potentially reducing dependence on frequent apheresis sessions. The clinical implications are significant. Access to lipoprotein apheresis remains limited in many regions due to cost, equipment requirements, and the need for specialized personnel. For patients without access to apheresis, evinacumab offers an effective alternative. For those already receiving apheresis, reducing treatment frequency could substantially improve quality of life, consistent with real-world evidence suggesting a lower treatment burden with evinacumab and potential improvements in quality of life. This evolving paradigm is particularly relevant in paediatric care. Lipoprotein apheresis has long been used in children with HoFH and remains essential when plasma pharmacological lipid-lowering therapies are insufficient or unavailable. Early initiation during childhood and adolescence is associated with reduced long-term ASCVD risk and mortality, particularly when performed frequently.6 However, apheresis is technically challenging in young children due to limitations in vascular access. Evinacumab is now approved for use in increasingly younger populations (for children aged 6 months and older in Europe, and for children aged 1 year and older in the US), thus offering the possibility of earlier and less invasive intervention during a critical period of cardiovascular risk development.2 However, evinacumab is not yet universally available, and alongside efforts to improve identification of patients with familial hypercholesterolaemia, ensuring equitable access to this therapy, particularly in less-resourced regions, remains a critical priority. Nevertheless, caution is warranted when interpreting these findings. This analysis is post hoc and descriptive, with inherent limitations. Differences in baseline characteristics, including genotype and background therapies, may have influenced outcomes. Notably, the reasons for changes in apheresis frequency were not recorded, and treatment adjustments were made without standardized criteria. Variability in clinical practice and potential differences in guideline adherence may have contributed to inconsistent decision-making. Consequently, the reported reduction in apheresis frequency in 29% of participants may underestimate the true potential for deintensification. At the same time, the lack of standardization introduces uncertainty, as changes in apheresis frequency may reflect factors beyond LDL-C reduction. These findings should therefore be considered hypothesis-generating. An area of growing interest is the combination of evinacumab with lomitapide. These drugs act through complementary LDLR-independent mechanisms—targeting lipoprotein clearance and production, respectively—and may be used together to achieve profound LDL-C reductions in HoFH, potentially allowing reduction or discontinuation of lipoprotein apheresis. Of note, in March 2026, the Food and Drug Administration approved an expansion of lomitapide for HoFH in children aged 2 years and older, while the European Medicines Agency EMA has issued a positive opinion recommending the approval of lomitapide for children aged 5 years and older. Although evidence remains limited, emerging data from case reports and small real-world studies are encouraging. In a 4-year-old with LDLR-null HoFH, adding evinacumab to lomitapide within an intensive regimen reduced LDL-C from 1005 mg/dL to less than 70 mg/dL, achieving guideline goals and preventing progression of premature coronary heart disease.7 Similar benefits have been observed in another young patient, including significant LDL-C reductions and regression of carotid plaque despite infrequent apheresis.8 In an adult patient, combination therapy with evinacumab and lomitapide has demonstrated sustained efficacy and acceptable safety, with marked LDL-C reductions (>90%) and regression of xanthomas and atherosclerotic plaques.9 Real-world data further suggest that adding evinacumab to lomitapide-based therapy can produce an additional ∼55% LDL-C reduction and enable discontinuation of apheresis in some patients.10 The current European Atherosclerosis Society consensus statement emphasizes that combining novel and conventional therapies is essential for managing HoFH and achieving LDL-C goals or reducing the need for apheresis.1 Looking ahead, several priorities emerge. Prospective studies are needed to define optimal strategies for combining or sequencing evinacumab and lipoprotein apheresis, including criteria for safely reducing apheresis frequency while maintaining adequate LDL-C control. Real-world data from international registries will be crucial to validate these findings and assess long-term outcomes. Clinical outcome data will also be required to confirm that LDL-C reductions translate into reduced cardiovascular burden and improved quality of life. In conclusion, the study by Moriarty et al.4 contributes to an evolving paradigm in HoFH management, shifting from rigid treatment algorithms to a flexible, patient-centred approach. Evinacumab may not replace existing therapies but may instead redefine their use, enabling effective LDL-C reduction while reducing treatment burden. In a condition requiring lifelong therapy, this shift may be as important as the magnitude of LDL-C reduction itself. ANGPTL3-lowering strategies represent a life-changing development in lipid therapeutics, extending beyond LDLR-dependent mechanisms and addressing the needs of patients who remain at high cardiovascular risk despite optimal conventional therapy. In this context, evinacumab serves as a complementary strategy that can be integrated with other therapies to maximize LDL-C reduction and improve outcomes in patients with HoFH. Looking to the future, the combination of evinacumab and lomitapide is particularly compelling: by coupling complementary mechanisms, it holds the potential to achieve greater LDL-C reductions in this extremely high-risk population, while allowing for lower lomitapide dosing and, consequently, a more favourable tolerability profile. Angela Pirillo (Writing—original draft [lead], Writing—review & editing [equal]), and Alberico Luigi Catapano (Writing—original draft [supporting], Writing—review & editing [equal]) The authors received no financial support for the authorship and/or publication of this article. Amarin, Amgen, Astrazeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, Viatris. ALC is in part supported by Ministero della Salute Ricerca Corrente. No new data were generated or analysed in support of this research.
No takes yet. Share an insight, caveat, or question.
Pirillo et al. (2026) conducted an editorial in Homozygous familial hypercholesterolaemia (n=138). Evinacumab with lipoprotein apheresis vs. Evinacumab without lipoprotein apheresis was evaluated on LDL-C reduction. Evinacumab achieved substantial and similar LDL-C reductions at 24 weeks in HoFH patients undergoing apheresis and those not receiving apheresis.
Synapse has enriched 10 related papers. Consider them for comparative context: